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Protein trafﬁcThe 1st International Workshop on Papillomavirus E5 Oncogene was held in Capri, Italy, 27–28 May 2010.
Here we present a brief report of the various lectures which addressed the multiple facets of the E5 protein..
l rights reserved.© 2010 Elsevier Inc. All rights reserved.The 1st International Workshop on Papillomavirus E5 Oncogene
was held at Villa Orlandi on the stunningly beautiful island of Capri,
Italy, organised by Giuseppe Borzacchiello and Franco Roperto,
University of Naples, Saveria Campo, University of Glasgow, and
Aldo Venuti, Regina Elena Institute for Cancer Research, Rome.
The workshop was held under the auspices of the International
Papillomavirus Society, the Italian Society of Virology, the Italian
Association for Veterinary Pathology and the European Society of
Veterinary Pathology. The purpose of the workshop was to bring
together the relatively small community of virologists stubborn
enough to work on the papillomavirus E5 oncoprotein in order to
stimulate in-depth discussion and promote understanding of the role
of E5, primarily HPV E5 and BPV E5, in cell transformation and the
virus life cycle. The workshop was a success. Most of the E5 virologists
from all over the world were able to attend, the presentations were
highly interesting and the discussion lively and energetic. (We will
talk about the food and wines later!).
First, a fewwords of introduction for the papillomavirus E5 protein
for the non-aﬁcionados. E5 is a small hydrophobic protein of 83 amino
acid residues in HPV-16, 44 in BPV-1 and 42 in BPV-4, the most
studied E5 proteins. E5 is located in the cell endomembrane
compartments, primarily the Golgi apparatus in the case of BPV E5
and the ER in the case of HPV E5. BPV E5 has a single passtransmembrane domain with short non-membrane associated N-
and C-termini on opposite sites of the membrane, N-terminus
cytoplasmic and C-terminus lumenal; HPV-16 E5 has three trans-
membrane pass domains and again the N- and C-terminus domains
are on opposite membrane sides, but in this case the N-terminus is
luminal and the C-terminus cytoplasmic. The BPV and HPV proteins
share functions but, generally speaking, BPV E5 is the more “potent”
protein, at least in terms of cell transformation (but see below the
presentation of Paul Lambert!). In this report, presentations on HPV
E5 will be dealt with ﬁrst, then those on BPV E5 and ﬁnally those on
the possibility of using E5 as a target for anti-papillomavirus therapy.
Given the location of E5 in the cell endomembranes, the workshop
was opened appropriately enough with a Plenary Lecture on the
functions of the Golgi apparatus delivered by Antonella De Matteis
(Naples), who emphasised that the Golgi is not a mere site of passage
of various biomolecules, but it has also regulatory functions in cell
cycle (the Golgi fragments at mitosis and blocking Golgi fragmenta-
tion stops mitosis) and signal transduction (many kinases and G
proteins are activated at the Golgi). It follows that either positive or
negative interference by E5 with any of these processes would have a
profound and cascade effect on many cell functions, such as signal
transduction, apoptosis, cell proliferation and stalling of protein
trafﬁc. Indeed the effect of E5 on these cellular processes was
discussed in the presentations that followed.
Dick Schlegel (Georgetown) presented data showing that E5
enhances signalling by EGF-R not so much by inhibition of endosome
acidiﬁcation, but by altering vesicle fusion events and therefore EGF
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observed E5 interference with the trafﬁc of MHC molecules,
cholesterol, gangliosides and lipid raft proteins. A very interesting
part of this presentation was the detection of E5 protein by mass
spectrometry. The presence of E5 protein, especially HPV E5, is often
inferred by the presence of “E5 mRNA” but detection of the protein
has proved almost insurmountably difﬁcult given the physical and
biological characteristics of the protein, such as extreme hydropho-
bicity, very low amounts and membrane localisation. Thus the actual
proof that HPV-16 E5 does exist in SiHa and CaSki cells, and
presumably in other cells in which E5 has been studied almost as an
act of faith, is very welcome indeed!
The interference of E5 with the cell membranes was conﬁrmed by
an additional presentation. Brian Ceresa (Oklahoma) reported the
formation of binucleated cells upon expression of E5. This seems to be
a property of E5 from high risk HPV only as it is not observed with E5
from HPV not associated with cancer, nor in cells expressing only E6
and E7. Binucleated cells are a result of cell–cell fusion rather than
endonuclear division. Although E5 binucleated cells fail to propagate,
the addition of E6E7 suppresses the cell cycle checkpoint and at least
some cells escape growth arrest and become transformed, a further
indication of synergy between E5 and the other HPV oncoproteins.
How does E5 promote cell-cell fusion? Does (at least some) E5 reside
on the plasma membrane mediating fusion directly? Or is it an
indirect effect exerted from the endomembranes? These points still
need resolution.
E5 increases cell motility and decreases cell adhesion to the
substrate. Eeva Auvinen (Helsinki) showed that several cellular
microRNAs are altered in cells expressing HPV-16 E5. Three micro-
RNAs signiﬁcantly altered by E5 are miR-203, miR-324–5p, both
down-regulated, and miR-146a, which is up-regulated. Interestingly
and gratifyingly, some of the targets of these microRNAs are the same
genes the expression of which has been found altered in previous
work by the same author, namely genes involved in cell motility,
adhesion and proliferation. How E5 affects microRNA expression
remains to be established.
E5-promoted activities were also studied in trophoblast and
cervical cells by Véronique Fontaine (Brussels). Because of their
invasive properties, trophoblast cells are a good model for studying
mobility and invasion. Although E5 on its own is toxic and impairs
viability, in the presence of E6 and E7 it reduces cell adhesiveness and
increases migration and invasiveness. These events are accompanied
and presumably partly caused by downregulation of E-cadherin and
upregulation of NF-κB and AP-1.
The impact of E5 on signal transduction was addressed also by
Francesca Belleudi (Rome). In particular E5 seems to interfere with
KGF-induced KGF-R transport to the degradative pathway. Immuno-
ﬂuorescence showed that the localization of endocytic dots
corresponding to internalized KGF-R is different in E5 expressing
cells compared to control cells, which display a more peripheral
distribution. These data suggest that E5 might be involved in the
shifting of KGF-R trafﬁcking from degradation to recycling, thus
potentiating the signal.
The role of HPV-16 E5 in skin and cervical cancer was addressed in
a Plenary Lecture, sponsored by the Association for International
Cancer Research, by Paul Lambert (Madison). Mice transgenic for E5,
expressed in the basal layer of epithelia under the control of the K14
promoter, develop hyperplasia and skin tumours, the severity of
which correlates with the expression level of E5. E5-induced
hyperplasia is dependent on EGF-R, in agreement with previous in
vitro studies in a number of laboratories. One interesting facet of
neoplastic progression in the K14E5 mice is that the exophytic
papillomas convert to endophytic ones before the onset of cancer. The
biological signiﬁcance of the inversion remains to be elucidated. The
K14E5 transgenic mice were also investigated in the context of
cervical cancer. When treated with oestrogen for 6 months, the micedevelop CIN I and CIN II but not frank carcinomas. In these conditions,
when combined with either HPV-16 E6 or E7, E5 induces more severe
neoplasia than in mice expressing only one oncogene, showing that
E5 contributes to the neoplastic phenotype. Even more interestingly
however, when oestrogen treatment continues for 9 months, E5
transgenic mice develop cervical carcinomas, thus uncovering the
ability of E5 to induce cancer on its own, independently of other
oncogenes. Does a similar process happen in humans? This is a
difﬁcult question to answer, but, given that many observations made
in transgenic mice have been conﬁrmed in humans, it would seem
reasonable to assume that E5 has a role in human cervical cancer. This
assumption goes somewhat against the widely accepted argument
that the E5 region is lost in cancers as a result of integration of the viral
genome in the E2 region. It is however to be kept in mind that
approximately 40% of cervical cancers maintain extrachromosomal
copies of the HPV genome capable of expressing E5. It is also possible
that E5 contributes to the early stages of carcinogenesis, and E6 and E7
take over later on. The recent detection of E5 protein in cells (see
above) should clarify this point.
Lou Laimins (Chicago) described the novel association of HPV-16
and HPV-31 E5 with Bap31 and A4. Bap31 is a chaperone involved in
quality control of, for instance, MHC molecules; A4 is a putative ion
channel protein of the endoplasmic reticulum; Bap31 and A4
physically interact with each other. E5 and Bap31 physically interact
and colocalise in perinuclear structures. Deletion of the C-terminus of
E5 does not affect colocalisation of the two proteins but prevents their
interaction. The biological signiﬁcance of this interaction is demon-
strated by the decrease in colony formation and impaired proliferative
capacity of E5 expressing cells upon the inhibition of Bap31. E5 also
binds and colocalises with A4 independently of Bap31, in fact the
addition of Bap31 destabilises the E5–A4 complex. How the
interaction between E5 and A4 contributes to cell transformation
remains to be established.
Bap31 featured also in the Plenary Lecture given by Saveria Campo
(Glasgow) who bridged the HPV and BPV E5 sessions by reporting the
effect of E5 proteins on the processing and surface expression of MHC
class I. Both BPV and HPV E5 retain MHC class I in the endomembrane
compartments, thus decreasing the number of MHC I molecules on
the cell surface. BPV E5 and HPV E5 both interact directly with the
heavy chain component of the MHC I complex, but they use different
domains: BPV-1 and BPV-4 E5 bind heavy chain via their C-terminus,
whereas HPV-16 E5 binds heavy chain via its ﬁrst transmembrane
domain, and precisely the leucine pairs present in this region.
Intriguingly, this E5 domain shows homology with the third
transmembrane domain of Bap31. Bap31 chaperones MHC I in its
transit to the cell surface. Putting together the data presented by
Laimins and Campo, a possible picture of the relationship between E5,
MHC I and Bap31 emerges, whereby membrane-bound E5 would
displace Bap31 from MHC I, maybe taking advantage of its own
interaction with Bap31, and thus retain MHC I in the ER/Golgi. As
MHC I is the main presenter of antigenic peptides to CD8+ cytotoxic T
lymphocytes (CTLs), its absence from the cell surface would have
profound effects on the recognition and elimination of infected cells.
Indeed, using mouse cells expressing human MHC I (HLA-A2) and E5
and loaded with an E6 peptide, Campo showed that E6 peptide-
speciﬁc CTLs are not capable of recognising these cells to the extent
they do control cells. It is therefore likely that E5 downregulates the
host immune response also during a natural infection, promoting the
persistence of transformed cells and thus neoplastic progression.
And so to BPV E5. In his Plenary Lecture Dan DiMaio (Yale)
discussed how BPV-1 E5 can be used as a scaffold for the generation of
small membrane-bound proteins that can modulate, say, receptors.
The primary mechanism by which BPV-1 E5 transforms cells is via the
binding and activation of the PDGF β receptor in absence of ligand.
Large libraries of small E5-like proteins randomised in their trans-
membrane domain were tested for their activities by focus forming
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even if they show no signiﬁcant homology with wild type E5. One
protein, selected for its ability to confer erythropoietin-independence
on growth factor depended cells, fails to activate the PDGF β receptor
but activates the human erythropoietin receptor (EPO-R) instead,
inducing erythroid differentiation and proliferation of human hemo-
poietic progenitor cells, with obvious pharmacological applications.
Other proteins were selected that inhibit cell surface expression of a G
protein-coupled receptor (GPCR). Because GCPRs have many physio-
logical activities, including acting as HIV receptors, this result raises
the exciting possibility of a reagent against HIV infection. Clearly there
is more to BPV-1 E5 than the induction of warts!
Maria Peleteiro (San Miguel, Azores) reported the results of a
survey of various molecular markers in bovine urinary bladder
tumours associated with BPV infection. Uroplakin III, a speciﬁc
urothelial marker, is lost in aggressive bladder tumours, suggesting
that it would be a goodmarker for the diagnosis of high grade cancers.
Conversely cyclin D1 and p53 are overexpressed in high grade
cancers. E5 is expressed in tumours conﬁrming its involvement in
bovine bladder carcinogenesis.
Nunzia Corteggio (Naples) from Borzacchiello's lab discussed
the signal transduction pathways induced by the activation of the
PDGFβ-R when bound to E5 in both equine sarcoids and bovine
urinary bladder cancer (see later for BPV and equine sarcoids).
PDGFβ-R and PI3K physically interact as do PDGFβ-R and the Grb2-
Sos complex. PI3K-Akt and Grb2-Sos-Mek-Erk signals are all poten-
tiated in cancer, but, as in in vitro models, the levels of Erk and Mek
proteins are not signiﬁcantly overexpressed. E5 therefore impacts on
signal transduction without altering the level of the proteins involved.
Sante Roperto (Naples) conﬁrmed the presence of E5 protein in
peripheral blood mononuclear cells of cattle suffering from urinary
bladder tumors expressing E5. Roperto deﬁned the subset of blood
cells that express E5 as primarily CD4 and CD8 T lymphocytes
although also B lymphocytes andmonocytes appear to be involved. E5
is detected in lymphocytes when the neoplastic lesions of the urinary
bladder are in the initial stages suggesting its early involvement in the
pathology. What could be the effect of E5 expression in lymphocytes?
E5 could inhibit bothMHC class I and class II thus profoundly disabling
the immunological role of blood cells. By inducing at the same time
the proliferation of blood cells it could also contribute to the spread of
infection via the blood stream. These tantalising possibilities remain
to be proven and further evidence of the action of E5 (and other BPV
proteins) in lymphocytes is eagerly awaited.
Although papillomaviruses are normally strictly species-speciﬁc,
BPV-1 can jump species and infect equids, causing a ﬁbroblastic
tumour called sarcoid. Both Lubna Nasir (Glasgow) and Sabine Brandt
(Vienna) discussed the role of BPV-1 in general and E5 in particular in
the pathology of sarcoids. Nasir showed that sarcoid cells are invasive
and degrade collagen. This aspect of equine cell transformation is at
least in part due to E5. E5 increases expression of matrix metallopro-
teinase 1 (MMP-1, collagenase), with increased degradation of
collagen and matrix invasion. How E5 increases MMP-1 and itsactivity is not yet clear. In theMMP-1 promoter there are AP-1 binding
sites which are essential for MMP-I transcription. However, although
E5 has been reported to activate AP-1, in this case it does not appear to
act on the MMP-1 promoter. An intriguing alternative is that E5
stabilises MMP-1 mRNA via an AU-rich stretch at the 3' end of the
RNA, but this possibility has not been tested.
Brandt showed conclusive evidence that BPV-1 infection in horses
does not involve only the derma, as so far believed, but also the
epidermis. Viral DNA and E5 RNA are found in the epidermis, although
in lesser amounts than in the dermis. The sequences of E5 in the
dermis and epidermis are the same, but different from wild type
“bovine” E5, as previously reported by the Nasir group. Another
interesting point presented by Brandt is the occasional presence of
BPV capsomeres in the epidermis of sarcoids, raising the exciting
possibility that the sarcoid may be productive for infectious virus,
contrary to what was hitherto believed.
Moving toward the clinical signiﬁcance of E5 research, Aldo Venuti
(Rome) showed that E5 interferes with apoptosis induced by taxanes.
In particular the paclitaxel-induced up-regulation of caspases 3 and
8 is dramatically inhibited by E5. Data from a limited number of
patients suggest that E5 expression may lead to a worse response to
treatment with taxanes.
Rosella Franconi (Rome) reported the production of recombinant
DNA vaccine expressing the BPV E5 protein fused to the coat protein
of PVX plant virus. This fusion enhanced the “visibility” of the tumour
antigen rendering more efﬁcacious the immunological response, at
least in a mousemodel. Starting clinical trials in cattle suffering of BPV
induced pathologies (i.e. enzootic haematuria/bladder carcinoma)
will ascertain the effectiveness of anti-E5 immunotherapy in
modifying the natural history of BPV-induced tumours.
Finally Lies Bogaert (Gent/Los Angeles) presented data on a
tumour mouse model expressing the E5-E6 proteins of BPV and on
the immunogenicity of 4 overlapping E5 peptides. All peptides were
able to bind to H-2Kb and H-2Db molecules and were thus suitable
candidates for vaccine. In particular the 19–36 E5 peptide was able to
stimulate the strongest immunological response in vaccinated mice
inducing higher number of IFN-gamma secreting splenocytes.
Two conclusions can be drawn from this last session. The ﬁrst is
that E5 can interfere negatively with some therapeutic treatments and
the second is that it can be used in immunotherapy. The neutralization
of E5 therefore, whether immunological or chemical, could be
advantageous in a variety of cancer treatments.
Thus, the science was great. Now, the promised description of food
and drinks. Not only the lunch was delightful, with pizza, mozzarella,
provolone, fresh tomato, pasta and other Mediterranean delicacies;
the Gala Dinner was absolutely amazing, with wave upon wave of sea
food dishes, from prawn to mussels, to tuna, to sword ﬁsh and any
other creature that ever swam in the sea. And the chilled, dry, white
wine kept coming too…… The reader will not be surprised to hear
that the potent combination of powerful science and great food left
the participants determined to have a 2nd, a 3rd, a 4th, etc. E5
workshop!
